Skip to content

A Rehabilitative Approach in Patients With Parkinson's Disease

Impact of Mézières Rehabilitative Method in Patients With Parkinson's Disease: a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02891473
Enrollment
36
Registered
2016-09-07
Start date
2015-07-31
Completion date
2016-01-31
Last updated
2017-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Posture, Pain, Muscle stretching, Mézières method, Camptocormia, Trunk control

Brief summary

The purpose of the study is to evaluate the effectiveness of a rehabilitative approach using breathing and relaxation techniques, and specifically the elongation of the latissimus dorsi muscle according to the Mézières Method to improve balance and posture and relief pain in patients with Parkinson's disease.

Interventions

OTHERMézières Method

10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.

1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis od idiopathic Parkinson's disease (according to UK Brain Bank Criteria), Hoehn-Yahr stage ≤3 (determined during on phase), Mini Mental State Examination (MMSE) \> or = 27, no rehabilitation treatment carried out within 3 months prior to the study, diagnosis of Parkinson's disease by at least 5 years.

Exclusion criteria

* Dyskinesias * Severe fluctuations on-off * Modifications of anti-Parkinsonian drug therapy during the three months prior to the start of the study) * Sensitivity deficit of the trunk or lower extremities (physical examination) * Vestibular disorders or paroxysmal vertigo * Previous thoracic or abdominal surgery * Other neurological or orthopedic conditions involving the trunk or lower extremities (musculoskeletal diseases, severe osteoarthritis, peripheral neuropathy, prosthetic surgery) * Cardiovascular comorbidities (recent myocardial infarction, heart failure, uncontrolled hypertension, orthostatic hypotension)

Design outcomes

Primary

MeasureTime frameDescription
Change of Berg Balance Scale (BBS) from baseline to 12 weeksBaseline, 4 weeks, 12 weeksIt is a widely used clinical tests to evaluate static and dynamic balance of a subject. The total score is 56 (\> 45 safe walking without aids/low tendency to fall, \> 35 safe walking with aids). The test lasts 15-20 minutes, and includes 14 simple tasks. The success in achieving each task is evaluated assigned a score from zero (dependent) to four (independent), and the final measure is the sum of all scores. The scale is considered the gold standard for providing useful information on the predictive estimation of the risk of falls.

Secondary

MeasureTime frameDescription
Change of Unified Parkinson's Disease Rating Scale (UPDRS) from baseline to 12 weeksBaseline, 4 weeks, 12 weeksIt consists of six parts made up of questions about the mental state, behavior and mood, ADL, motor functions, the complications of the advanced disease, the stage of the disease identified by the Hoehen and Yahr scale and the modification in the execution of the ADL trough the scale of Schwab and England. The scale is based on a metric scale from 0 (no disability) to 147 points (severe disability).
Change of Functional Gait Assessment (FGA) from baseline to 12 weeksBaseline, 4 weeks, 12 weeksIt is a 10-items scale that measures walking balance activity and it was developed from the Dynamic Gait Index (DGI) to improve reliability and decrease the ceiling effect. Each item is scored on a 3 point-scale from 0 (severe impairment) to 3 (normal deambulation). The highest possible score is 30 (normal gait function).
Change of Visual Analogue Scale (VAS) from baseline to 12 weeksBaseline, 4 weeks, 12 weeksIt is a scale for the assessment of pain and it's based on a ten point scale, where 0 means no pain and 10 the greatest pain ever both at rest and during movements.
Change of Modified Parkinson Activity Scale (MPAS) from baseline to 12 weeksBaseline, 4 weeks, 12 weeksconsists of 14 items arranged into three domains, chair transfer, gait akinesia and bed mobility. Scores range from 0 (dependent) to 4 (normal) and the total possible score is 56.
Change of SF-36 Health Survey Questionnaire from baseline to 12 weeksBaseline, 4 weeks, 12 weeksIt is a multi-dimensional questionnaire for the evaluation of health status. It is divided into eight sub-categories that measure physical activity, limitations due to physical health and emotional state, physical pain, the perception of general health, vitality, social activities, mental health and changes in health status and two indices that summarize the overall assessment of the subject with respect to his/her physical (ISF) and mental (ISM) health.
Change of Clinical Evaluation of Posture from baseline to 12 weeksBaseline, 4 weeks, 12 weeksIt is the evaluation of the anterior flexion of the trunk by measuring the distance fingers-floor.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026